Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BHB Supplementation in Crohn's Disease
NCT06351124Phase 2Recruiting
- Sponsor
- University of Texas at Austin
- Start
- Aug 2024
- Primary completion
- Apr 2025
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial (2 arms), sponsored by University of Texas at Austin. Primary endpoints: Ability to enroll patients who meet the inclusion criteria within the target time frame at 12 months, Adherence to proposed study timelines and anticipated study costs at 12 months and 1 more. Started Aug 2024; status: recruiting.
Beyond the preview
Go deeper on NCT06351124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06351124.